Fusion Antibodies plc

Default features description for sign up page.

Updates

Regulatory News

Company Presentations

Webinars

Board Profiles

Company Profile

Home

Fusion Deep Dive

Advisers

Company Information & FAQs

Corporate Governance

Share Price

New investors

Shareholder Information

Raleway

Fusion Antibodies are pleased to announce a second collaboration with Aerpio Therapeutics to apply our CDRx Antibody Humanization platform to Aerpio’s Mouse Monoclonal Antibody.

Fusion Antibodies Ltd are excited to announce our second collaboration with Aerpio Therapeutics, of Cincinnati, Ohio. Aerpio are biopharmaceutical company focused on advancing first-in-class treatments for the eye. Following the success of the companies’ first antibody development program, completed in 2015, Fusion Antibodies has now initiated a second antibody humanization program with Aerpio.

The partnership caps another record-breaking year for Fusion Antibodies’ Humanization service. In the past 12 months more than 30 projects have been completed. Paul Kerr, Managing Director of Fusion Antibodies – “We are excited to have the opportunity to extend our collaboration with the team at Aerpio and look forward to delivering a panel of quality humanized antibodies using our CDRx platform. The work Aerpio Therapeutics is doing on diabetic eye disease is cutting edge and very exciting to be part of.” Kevin Peters, Aerpio Therapeutics’ Chief Scientific Officer, stated, “We’re pleased to begin our second antibody humanization program with Fusion Antibodies. The first project went very well and yielded multiple humanized clinical candidates. The success of the first program was a tribute to the experience and knowledge of the Fusion Antibodies team and to the collaborative nature of the Fusion culture.”

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of vascular disorders with an emphasis on diseases of the eye. Aerpio is a leader in the development of therapeutics based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class small molecule stabilizer of the Tie2 pathway and is in clinical development for diabetic eye disease. More information is available at www.aerpio.com.

Fusion Antibodies announces collaboration with Aerpio Therapeutics for second Antibody Humanization project